Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alliancaude e ParticipacoesBSP:AALR3 -1.54%49 EBITDA Margin % is 23.72% as of Sep. 2025, which is 60% above its 10-year median of 14.79. GuruFocus rates BSP:AALR3 with a GF Score™ of 49/100 and a GF Value™ of R$9.40 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Alliancaude e Participacoes ranks better than 67.16% on this metric.
Alliancaude e Participacoes (BSP:AALR3) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Alliancaude e Participacoes EBITDA Margin % Related Terms
Alliancaude e Participacoes EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:AALR3 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Alliancaude e Participacoes's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alliancaude e Participacoes EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Alliancaude e Participacoes's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Alliancaude e Participacoes's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alliancaude e Participacoes (BSP:AALR3) has a EBITDA Margin % of 23.72% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alliancaude e Participacoes and its competitors. This is 60% above median its historical median of 14.79. Over the past decade, Alliancaude e Participacoes' EBITDA Margin % has ranged from 6.88 to 22.85. According to the industry distribution chart, Alliancaude e Participacoes ranks #67 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 32.8%.
Is Alliancaude e Participacoes' EBITDA Margin % too high?
Alliancaude e Participacoes' current EBITDA Margin % of 23.72% is 60% above median its 10-year median of 14.79. Over the past 10 years, this metric has ranged from a low of 6.88 to a high of 22.85. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.22. Alliancaude e Participacoes' value of 23.72% is 354.8% above this industry median. Based on the distribution chart, Alliancaude e Participacoes ranks #67 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Alliancaude e Participacoes has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alliancaude e Participacoes' EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Alliancaude e Participacoes ranks #67 out of 204 companies for EBITDA Margin %. This puts Alliancaude e Participacoes in the upper half of its industry. The industry median EBITDA Margin % is 5.22. Alliancaude e Participacoes' value of 23.72% is 354.8% above this benchmark. Historically, Alliancaude e Participacoes' own EBITDA Margin % has ranged from 6.88 to 22.85 over the past decade. While the company's 10-year median is 14.79 vs. the industry median of 5.22, Alliancaude e Participacoes has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.22, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alliancaude e Participacoes's current EBITDA Margin % of 23.72% is 354.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alliancaude e Participacoes and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alliancaude e Participacoes's current EBITDA Margin % is 23.72%, which is 60% above median its own 10-year median of 14.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alliancaude e Participacoes stock overvalued right now?
Based on GuruFocus' analysis, Alliancaude e Participacoes (BSP:AALR3) is currently considered Possible Value Trap. The stock's GF Value™ is R$9.40, compared to a current price of R$3.20 — trading 66% below its estimated fair value. The current EBITDA Margin % is 23.72%, which is 60% above median its 10-year median of 14.79 and 354.8% above the Medical Diagnostics & Research industry median of 5.22. Alliancaude e Participacoes' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Alliancaude e Participacoes (BSP:AALR3), the current EBITDA Margin % is 23.72% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alliancaude e Participacoes (BSP:AALR3) Overvalued in 2026?
Based on GuruFocus' analysis, Alliancaude e Participacoes stock appears to be undervalued.
The current stock price of R$3.20 is trading 66% below its estimated GF Value™ of R$9.40.
GuruFocus considers Alliancaude e Participacoes to be Possible Value Trap.
Key valuation signals for BSP:AALR3:
EBITDA Margin %: 23.72% (60% above median its 10-year median of 14.79)
GF Value™: R$9.40 vs. price of R$3.20 (66% below fair value)
Industry Position: 354.8% above the Medical Diagnostics & Research median (#67 of 204)
No single metric tells the full story. See the BSP:AALR3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Allianca Saude e Participacoes SA formerly Centro de Imagem Diagnosticos SA - Alliar is a diagnostic imaging company consisting of MRI machines, CT scanners and ultrasound machines. Its products include diagnostic medicine, diagnostic imaging and clinical analysis. The company is also engaged in the import of medical and hospital equipment, diagnosis kits, and related goods; Providing health consulting, advisory, courses and lectures.
49GF Score
Get the complete analysis for BSP:AALR3
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:AALR3 has been successfully added to your 
